MPO

Across TCGA pan-cancer cohorts, MPO mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MPO data layer compared with 29 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MPO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MPO expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MPO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	36	view →
LUAD	OS	Quartile	III,IV	0.218	0.787	.006	23	view →
PDAC	OS	Tertile	III,IV	0.274	0.876	.012	12	view →
HNSC	OS	Quartile	All	0.967	0.797	.019	7	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MPO–CCRCC (DFS)

Open the CCRCC breakdown →